References
- 1. A. Bielecka-Dabrowa, D. P. Mikhailidis, S. Hannam, W. S. Aronow, J. Rysz and M. Banach, Statins and dilated cardiomyopathy: do we have enough data, Expert Opin. Investig. Drugs 20 (2011) 315-323; DOI: 10.1517/13543784.2011.550570.10.1517/13543784.2011.55057021210757
- 2. M. Touvron, B. Escoubet, M. Mericskay, A. Angelini, L. Lamotte, M. P. Santini, N. Rosenthal, D. Daegelen, D. Tuil and J. F. Decaux, Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction, Dis. Model. Mech. 5 (2012) 481-491; DOI: 10.1242/dmm.009456.10.1242/dmm.009456338071122563064
- 3. L. Werner, V. Deutsch, I. Barshack, H. Miller, G. Keren and J. George, Transfer of endothelial progenitor cells improves myocardial performance in rats with dilated cardiomyopathy induced following experimental myocarditis, J. Mol. Cell. Cardiol. 39 (2005) 691-697; DOI: 10.1016/ j.yjmcc.2005.06.015.10.1016/j.yjmcc.2005.06.01516125196
- 4. E. Hoshikawa, Y. Matsumura, T. Kubo, M. Okawa, N. Yamasaki, H. Kitaoka, T. Furuno, J. Takata and Y. L. Doi, Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy, Am. J. Cardiol. 107 (2011) 1065-1070; DOI: 10.1016/j.amjcard.2010.11.033.10.1016/j.amjcard.2010.11.03321296328
- 5. W. B. Zhang, Du QJ, H. Li, A. J. Sun, Z. H. Qiu, C. N.Wu, G. Zhao, H. Gong, K. Hu, Y. Z. Zou and J. B. Ge, The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats, J. Cell. Mol. Med. 16 (2012) 2227-2237; DOI: 10.1111/j.1582-4934.2012.01536.x.10.1111/j.1582-4934.2012.01536.x382299222288611
- 6. J. J. Goldberger, H. Subacius, A. Schaechter, A. Howard, R. Berger, A. Shalaby, J. Levine and A. H. Kadish, Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy, J. Am. Coll. Cardiol. 48 (2006) 1228-1233; DOI: 10.1016/j.jacc. 2006.05.053.
- 7. F. Tehrani, R. Morrissey, A. Phan, C. Chien and E. R. Schwarz, Statin therapy in patients with diastolic heart failure, Clin. Cardiol. 33 (2010) E1-E5; DOI: 10.1002/clc.20615.10.1002/clc.20615665329520127896
- 8. S. K. Thambidorai, A. R. Deshmukh, R. W. Walters, P. D. Turner,M. S.Monaghan, A. N. Mooss, C. B. Hunter, D. J. Esterbrooks and S. M. Mohiuddin, Impact of statin use on heart failure mortality, Int. J. Cardiol. 147 (2011) 438-443; DOI: 10.1016/j.ijcard.2010.08.016.10.1016/j.ijcard.2010.08.01620971517
- 9. T. Sakamoto, S. Kojima, H. Ogawa, H. Shimomura, K. Kimura, Y. Ogata, N. Sakaino and A. Kitagawa, Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese, Am. J. Cardiol. 97 (2006) 1165-1171; DOI: 10.1016/ j.amjcard.2005.11.031.10.1016/j.amjcard.2005.11.03116616020
- 10. R. Jarai, C. Kaun, T. W. Weiss, W. S. Speidl, K. Rychli, G. Maurer, K. Huber and J. Wojta, Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, J. Cell. Mol. Med. 13 (2009) 4415-4421; DOI: 10.1111/j.1582-4934.2009.00704.x.10.1111/j.1582-4934.2009.00704.x451505719228263
- 11. P. E. Lazzerini, P. L. Capecchi and F. Laghi-Pasini, Statins as a new therapeutic perspective in myocarditis and postmyocarditis dilated cardiomyopathy, Cardiovasc. Drugs Ther. 27 (2013) 365-369; DOI: 10.1007/s10557-013-6475-8.10.1007/s10557-013-6475-823832693
- 12. Y. Kameda, H. Hasegawa, A. Kubota, H. Tadokoro, Y. Kobayashi, I. Komuro and H. Takano, Effects of pitavastatin on pressure overload-induced heart failure in mice, Circ. J. 76 (2012) 1159-1168; DOI: 10.1253/circj.CJ-11-1114.10.1253/circj.CJ-11-1114
- 13. T. Aoyagi, F. Nakamura, T. Tomaru and T. Toyo-Oka, Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure, Int. Heart J. 49 (2008) 49-58; DOI: 10.1536/ihj.49.49.10.1536/ihj.49.4918360064
- 14. H. Takano, H. Mizuma, Y. Kuwabara, Y. Sato, S. Shindo, N. Kotooka, D. Fujimatsu, Y. Kobayashi, T. Inoue, K. Node and I. Komuro, Effects of pitavastatin in Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study), Circ. J. 77 (2013) 917-925; DOI: 10.1253/circj.CJ-12-1062.10.1253/circj.CJ-12-106223502990
- 15. J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J. G. Cleland, J. H. Cornel, P. Dunselman, C. Fonseca, A. Goudev, P. Grande, L. Gullestad, A. Hjalmarson, J. Hradec, A. Janosi, G. Kamensky, M. Komajda, J. Korewicki, T. Kuusi, F. Mach, V. Mareev, J. J. McMurray, N. Ranjith, M. Schaufelberger, J. Vanhaecke, D. J. van Veldhuisen, F. Waagstein, H. Wedel and J. Wikstrand, Rosuvastatin in older patients with systolic heart failure, N. Engl. J. Med. 357 (2007) 2248-2261; DOI: 10.1056/NEJMoa0706201.10.1056/NEJMoa070620117984166
- 16. S. A. Chang, Y. J. Kim, H. W. Lee, D. H. Kim, H. K. Kim, H. J. Chang, D. W. Sohn, B. H. Oh and Y. B. Park, Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy, Hypertension 54 (2009) 591-597; DOI: 10.1161/HYPERTENSIONAHA.109.131243.10.1161/HYPERTENSIONAHA.109.13124319564547
- 17. K. Krishnamurthy, R. Kanagasabai, L. J. Druhan and G. Ilangovan, Heat shock protein 25-enriched plasma transfusion preconditions the heart against doxorubicin-induced dilated cardiomyopathy in mice, J. Pharmacol. Exp. Ther. 341 (2012) 829-839; DOI: 10.1124/jpet.112.192245.10.1124/jpet.112.192245336288022438470
- 18. F.N.Gava, E. Zacche, E.M.Ortiz, T. Champion,M. B. Bandarra, R. O. Vasconcelos, J. C. Barbosa and A. A. Camacho, Doxorubicin induced dilated cardiomyopathy in a rabbit model: an update, Res. Vet. Sci. 94 (2013) 115-121; DOI: 10.1016/j.rvsc.2012.07.027.10.1016/j.rvsc.2012.07.02722902286
- 19. K. Suzuki, B. Murtuza, N. Suzuki, R. T. Smolenski andM. H. Yacoub, Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure, Circulation 104 (2001) 1213-1217; DOI: 10.1161/hc37t1.094929.10.1161/hc37t1.09492911568058
- 20. M. Sano, T. Minamino, H. Toko, H. Miyauchi, M. Orimo, Y. Qin, H. Akazawa, K. Tateno, Y. Kayama, M. Harada, I. Shimizu, T. Asahara, H. Hamada, S. Tomita, J. D. Molkentin, Y. Zou and I. Komuro, p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload, Nature 446 (2007) 444-448; DOI: 10.1038/nature05602.10.1038/nature0560217334357
- 21. Y. C. Liao, Y. C. Hsieh, C. Y. Hung, J. L. Huang, C. H. Lin, K. Y.Wang and T. J. Wu, Statin therapy reduces the risk of ventricular arrhythmias, sudden cardiac death, and mortality in heart failure patients: A nationwide population-based cohort study, Int. J. Cardiol. 2013, in press; DOI: 10.1016/j.ijcard.2013.07.036.10.1016/j.ijcard.2013.07.03623890884
- 22. A. Tidholm, J. Haggstrom and K. Hansson, Effects of dilated cardiomyopathy on the renin- -angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs, Am. J. Vet. Res. 62 (2001) 961-967; DOI: 10.2460/ajvr.2001.62.961.10.2460/ajvr.2001.62.96111400857
- 23. X. Y. Tian, W. T. Wong, A. Xu, Z. Y. Chen, Y. Lu, L. M. Liu, V. W. Lee, C.W. Lau, X. Yao and Y. Huang, Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress, Br. J. Pharmacol. 164 (2011) 598-606; DOI: 10.1111/j.1476-5381. 2011.01416.x.
- 24. H. Toba, T. Mitani, T. Takahashi, N. Imai, R. Serizawa, J. Wang, M. Kobara and T. Nakata, Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes, Clin. Exp. Pharmacol. Physiol. 37 (2010) 1064-1070; DOI: 10.1111/j.1440-1681.2010.05436.x.10.1111/j.1440-1681.2010.05436.x20678154
- 25. G. Nickenig and D. G. Harrison, The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis, Circulation 105 (2002) 393-396; DOI: 10.1161/hc0302.102618.10.1161/hc0302.10261811804998
- 26. S. L. Belmonte, B. C. Blaxall, PKC-ing is believing: targeting protein kinase C in heart failure, Circ. Res. 109 (2011) 1320-1322; DOI: 10.1161/CIRCRESAHA.111.259358.10.1161/CIRCRESAHA.111.25935822158646
- 27. A. L. Beck, M. E. Otto, L. B. D’Avila, F. M. Netto, M. K. Armendaris and A. C. Sposito, Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals, Atherosclerosis 222 (2012) 444-448; DOI: 10.1016/j.atherosclerosis. 2012.03.030.
- 28. X. Zhou, D. Shang, T. Zhang, L. Li, T. Zhou and W. Lu, Modeling of angiotensin II-angiotensin-( 1 ) counterbalance in disease progression in spontaneously hypertensive rats treated with/ without perindopril, Pharmacol. Res. 66 (2012) 177-184; DOI: 10.1016/j.phrs.2012.04.001.10.1016/j.phrs.2012.04.00122513176
- 29. M. J. Crespo, N. Cruz, P. I. Altieri and N. Escobales, Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster, J. Cardiovasc. Pharmacol. Ther. 13 (2008) 199-206; DOI: 10.1177/1074248408320006.10.1177/107424840832000618593848
- 30. M. R. O’Grady, M. L. O’Sullivan, S. L. Minors and R. Horne, Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers, J. Vet. Intern. Med. 23 (2009) 977-983; DOI: 10.1111/j.1939-1676.2009.0346.x.10.1111/j.1939-1676.2009.0346.x19572914
- 31. G. Pela, P. Pattoneri, M. Passera, G. Tirabassi, C. Reverberi, A. Montanari and T. Gherli, Long- -term effects of perindopril on left ventricular structure and function in patients with stable coronary artery disease: a conventional and Doppler tissue echocardiographic pilot study, J. Cardiovasc. Med. (Hagerstown) 10 (2009) 781-786; DOI: 10.2459/JCM.0b013e32832dbfe9. 10.2459/JCM.0b013e32832dbfe919525856